Publicações

Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study

AuthID
P-00Y-PBS

Author(s)

Pacheco, P

Marques, N

Rodrigues, P

Mansinho, K

Maltez, F

Janeiro, N

Franco, C

Trigo, D

Batista, J

Duque, L

[+1]·

Aleixo, MJ

Silva, AR

Tavares, R

Alves, J

Peres, S

Povoas, D

Lino, S

Gomes, P

Araujo, V

Lopes, C

View all authors

Tipo de Documento

Article in Press

Year published

2023

Publicado

in CLINICAL INFECTIOUS DISEASES, ISSN: 1058-4838

Volume: 77, Número: 5, Páginas: 740-748 (10)

Indexing

Wos^®

Scopus^®

Crossref^®3

Pubmed^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1093/cid/ciad339

Pubmed: 37288954

SCOPUS: 2-s2.0-85170717511

Wos: WOS:001018618800001

Source Identifiers

ISSN: 1058-4838

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

All authors

Name Order	Nome	Name Order	Nome	Name Order	Nome
1	Pacheco, P;	2	Marques, N;	3	Rodrigues, P;
4	Mansinho, K;	5	Maltez, F;	6	Janeiro, N;
7	Franco, C;	8	Trigo, D;	9	Batista, J;
10	Duque, L;	11	Lopes, MJ;	12	Aleixo, MJ;
13	Silva, AR;	14	Tavares, R;	15	Alves, J;
16	Peres, S;	17	Povoas, D;	18	Lino, S;
19	Gomes, P;	20	Araujo, V;	21	Lopes, C;

Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results From a 48-Week Phase 2 Study

Links Úteis

Ajuda